Details of the Drug Combination

General Information of Drug Combination (ID: DCVR76N)

• Drug Combination Name: Lovastatin + Paclitaxel
• Indication: Ovarian Cancer; Status: Phase 1 [1]
• Component Drugs:
  Lovastatin (DM9OZWQ): Small molecular drug
  Paclitaxel (DMLB81S): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Lovastatin

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[2]
Hypercholesterolaemia	5C80.0	Approved	[3]
Hyperlipidemia	5C80.Z	Approved	[2]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[2]
Hypertriglyceridemia	5C80.1	Approved	[2]
Melanoma	2C30	Approved	[2]
X-linked chondrodysplasia punctata 2	N.A.	Approved	[2]
Cardiovascular disease	BA00-BE2Z	Phase 3	[4]
Smith-Lemli-Opitz syndrome	N.A.	Investigative	[2]

Lovastatin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[6]

Lovastatin Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[8]

Lovastatin Interacts with 7 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[9]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[10]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[10]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Metabolism	[10]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Metabolism	[10]
Serum paraoxonase/lactonase 3 (PON3)	DETXQZ1	PON3_HUMAN	Metabolism	[11]

Lovastatin Interacts with 73 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Activity	[12]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[13]
Serum paraoxonase/lactonase 3 (PON3)	OT80W9TA	PON3_HUMAN	Increases Hydrolysis	[14]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Decreases Activity	[15]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Transport	[15]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Increases Expression	[16]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Cleavage	[17]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[18]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[19]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Increases Activity	[20]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Decreases Activity	[15]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Increases Expression	[16]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Increases Expression	[16]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[21]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[22]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Expression	[23]
GTPase NRas (NRAS)	OTVQ1DG3	RASN_HUMAN	Decreases Prenylation	[24]
GTPase HRas (HRAS)	OTWQN0DP	RASH_HUMAN	Decreases Prenylation	[24]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Prenylation	[24]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Increases Expression	[25]
Thyroglobulin (TG)	OT3ELHIJ	THYG_HUMAN	Increases Secretion	[26]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Activity	[27]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Secretion	[25]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[28]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Increases Cleavage	[29]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[30]
Tyrosine 3-monooxygenase (TH)	OT6ZORKP	TY3H_HUMAN	Increases Expression	[31]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Decreases Expression	[27]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[32]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[17]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[33]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Expression	[27]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Decreases Expression	[28]
Neuromodulin (GAP43)	OT2OTGGV	NEUM_HUMAN	Increases Expression	[31]
Lamin-B1 (LMNB1)	OT100T3P	LMNB1_HUMAN	Decreases Farnesylation	[34]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[35]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Activity	[30]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[27]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[27]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Decreases Expression	[30]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[36]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[17]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Expression	[37]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Affects Localization	[17]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[35]
Caspase-2 (CASP2)	OTUDYSPP	CASP2_HUMAN	Increases Activity	[18]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[30]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[25]
Centromere protein F (CENPF)	OT7AG0SW	CENPF_HUMAN	Increases Expression	[38]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Decreases Phosphorylation	[39]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Response To Substance	[40]
Caspase-6 (CASP6)	OTXLD3EC	CASP6_HUMAN	Increases Activity	[41]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Expression	[36]
Cell division control protein 42 homolog (CDC42)	OT5QBC5M	CDC42_HUMAN	Increases Expression	[23]
Transforming protein RhoA (RHOA)	OT6YOJ9N	RHOA_HUMAN	Decreases Prenylation	[24]
Actin, aortic smooth muscle (ACTA2)	OTEDLG8E	ACTA_HUMAN	Decreases Expression	[42]
Rho-related GTP-binding protein RhoB (RHOB)	OTHQFQF7	RHOB_HUMAN	Decreases Prenylation	[24]
Ras-related protein Rap-1A (RAP1A)	OT5RH6TI	RAP1A_HUMAN	Increases Expression	[38]
Ras-related C3 botulinum toxin substrate 1 (RAC1)	OTKRO61U	RAC1_HUMAN	Decreases Activity	[27]
HLA class II histocompatibility antigen, DR beta 3 chain (HLA-DRB3)	OT5PM9N7	DRB3_HUMAN	Affects Expression	[43]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[33]
Sterol regulatory element-binding protein 2 (SREBF2)	OTBXUNPL	SRBP2_HUMAN	Increases Localization	[25]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Affects Activity	[44]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[45]
Lymphoid enhancer-binding factor 1 (LEF1)	OTWS5I5H	LEF1_HUMAN	Affects Localization	[39]
A-kinase anchor protein 7 isoforms alpha and beta (AKAP7)	OT0L3PZ6	AKA7A_HUMAN	Decreases Response To Substance	[46]
Beta-parvin (PARVB)	OT9OGVWX	PARVB_HUMAN	Decreases Response To Substance	[46]
Metalloreductase STEAP2 (STEAP2)	OTGE9ETG	STEA2_HUMAN	Decreases Response To Substance	[46]
Interleukin-2 (IL2)	OTGI4NSA	IL2_HUMAN	Increases ADR	[47]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Increases ADR	[47]
Phosphatidate phosphatase LPIN2 (LPIN2)	OTRRTMXX	LPIN2_HUMAN	Decreases Response To Substance	[46]
ELL-associated factor 2 (EAF2)	OTSOET5L	EAF2_HUMAN	Decreases Response To Substance	[46]
Ankyrin-2 (ANK2)	OTWB4R1Y	ANK2_HUMAN	Decreases Response To Substance	[46]

Indication(s) of Paclitaxel

Disease Entry	ICD 11	Status	REF
Breast carcinoma	N.A.	Approved	[5]
Cutaneous melanoma	2C30	Approved	[5]
Cutaneous squamous cell carcinoma	2C30	Approved	[5]
Epithelial ovarian cancer	2B5D	Approved	[5]
Extragonadal germ cell tumor	N.A.	Approved	[5]
Fallopian tube neoplasm	N.A.	Approved	[5]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[5]
Inflammatory breast cancer	2C62	Approved	[5]
Kaposi sarcoma	2B57	Approved	[5]
Lung adenocarcinoma	N.A.	Approved	[5]
Lung cancer	2C25.0	Approved	[5]
Non-small-cell lung cancer	2C25.Y	Approved	[5]
Ocular hypertension	9C61.01	Approved	[5]
Ovarian neoplasm	N.A.	Approved	[5]
Ovarian serous cystadenocarcinoma	N.A.	Approved	[5]
Pain	MG30-MG3Z	Approved	[5]
Pancreatic ductal carcinoma	2C10.0	Approved	[5]
Primary peritoneal carcinoma	N.A.	Approved	[5]
Testicular germ cell tumor	N.A.	Approved	[5]
Urethral cancer	2C93	Approved	[5]
Lung large cell carcinoma	N.A.	Investigative	[5]

Paclitaxel Interacts with 11 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[60]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[61]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[62]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[63]
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[64]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[65]
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[66]
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[67]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[68]
TAP-like protein (ABCB9)	DT68UV2	ABCB9_HUMAN	Substrate	[69]
Multidrug resistance-associated protein 7 (ABCC10)	DTPS120	MRP7_HUMAN	Substrate	[70]

Paclitaxel Interacts with 478 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Decreases Expression	[71]
ATP-binding cassette sub-family C member 10 (ABCC10)	OT2JRWWJ	MRP7_HUMAN	Increases Expression	[72]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Expression	[72]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Decreases Response To Substance	[73]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[74]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Response To Substance	[75]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Decreases Response To Substance	[76]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Increases Transport	[64]
Cyclin-dependent kinase 20 (CDK20)	OTOLNN68	CDK20_HUMAN	Decreases Expression	[77]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Increases ADR	[47]
Lipoprotein lipase (LPL)	OTTW0267	LIPL_HUMAN	Increases ADR	[47]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[78]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[79]
TNF receptor-associated factor 1 (TRAF1)	OTTLM5RU	TRAF1_HUMAN	Decreases Expression	[77]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Decreases Expression	[80]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[80]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[52]
Poly polymerase 1 (PARP1)	OTIESHK4	PARP1_ARATH	Increases ADR	[47]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[81]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Increases Activity	[82]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[83]
Dihydropyrimidine dehydrogenase (DPYD)	OTWRF2NR	DPYD_HUMAN	Decreases Expression	[48]
Arylamine N-acetyltransferase 1 (NAT1)	OTCCNQ3H	ARY1_HUMAN	Decreases Activity	[84]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	OTAYZMOY	SIR1_HUMAN	Decreases Expression	[85]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Decreases Expression	[78]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Increases Expression	[78]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Decreases Activity	[86]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Decreases Activity	[86]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Decreases Activity	[86]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[87]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[88]
DNA fragmentation factor subunit alpha (DFFA)	OTFPFMT8	DFFA_HUMAN	Decreases Expression	[50]
Sulfhydryl oxidase 1 (QSOX1)	OT4ZPK4P	QSOX1_HUMAN	Decreases Expression	[49]
Serine/threonine-protein kinase PLK4 (PLK4)	OTV8KZDZ	PLK4_HUMAN	Decreases Expression	[49]
TNF receptor-associated factor 5 (TRAF5)	OTSBTLO0	TRAF5_HUMAN	Decreases Expression	[49]
Myc box-dependent-interacting protein 1 (BIN1)	OTK8O0X8	BIN1_HUMAN	Increases Expression	[89]
Nucleoside diphosphate kinase, mitochondrial (NME4)	OT2JTT42	NDKM_HUMAN	Decreases Expression	[50]
Potassium channel subfamily K member 3 (KCNK3)	OTWMAV6G	KCNK3_HUMAN	Increases Expression	[50]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Increases Expression	[80]
Acyl-coenzyme A thioesterase 8 (ACOT8)	OTHY684G	ACOT8_HUMAN	Decreases Expression	[90]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Expression	[91]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[88]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Increases Expression	[89]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Increases Expression	[92]
Mitogen-activated protein kinase 13 (MAPK13)	OT0W9GE7	MK13_HUMAN	Increases Expression	[50]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[93]
High affinity copper uptake protein 1 (SLC31A1)	OTXLRTUB	COPT1_HUMAN	Increases Expression	[72]
ATP-binding cassette sub-family C member 5 (ABCC5)	OT34G4US	MRP5_HUMAN	Increases Expression	[72]
N-glycosylase/DNA lyase (OGG1)	OTJ97TF3	OGG1_HUMAN	Increases Expression	[50]
Retinoschisin (RS1)	OTEW1ZM5	XLRS1_HUMAN	Decreases Secretion	[94]
Kunitz-type protease inhibitor 2 (SPINT2)	OTQV7BKQ	SPIT2_HUMAN	Decreases Expression	[89]
Adenylate cyclase type 6 (ADCY6)	OTFOY4WW	ADCY6_HUMAN	Decreases Expression	[49]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Increases Expression	[92]
Mitotic checkpoint protein BUB3 (BUB3)	OTU91HAU	BUB3_HUMAN	Increases Expression	[50]
Phospholipid phosphatase 2 (PLPP2)	OT0BQAXX	PLPP2_HUMAN	Decreases Expression	[89]
Myelin protein zero-like protein 2 (MPZL2)	OTKFNDUI	MPZL2_HUMAN	Decreases Expression	[89]
Dual specificity protein phosphatase CDC14B (CDC14B)	OTAESVOZ	CC14B_HUMAN	Decreases Expression	[77]
Hyaluronan mediated motility receptor (HMMR)	OT4M0JTZ	HMMR_HUMAN	Decreases Expression	[50]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1)	OTY9R6FZ	ERN1_HUMAN	Increases Expression	[95]
Death effector domain-containing protein (DEDD)	OTIL349E	DEDD_HUMAN	Decreases Expression	[49]
Serine hydrolase RBBP9 (RBBP9)	OT0Z04L6	RBBP9_HUMAN	Decreases Expression	[49]
Tumor necrosis factor ligand superfamily member 13 (TNFSF13)	OT90OWIO	TNF13_HUMAN	Increases Expression	[77]
ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial (CLPX)	OTIT4JL0	CLPX_HUMAN	Increases Expression	[50]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Increases Expression	[77]
Securin (PTTG1)	OTIMYS4W	PTTG1_HUMAN	Affects Expression	[96]
G1/S-specific cyclin-E2 (CCNE2)	OTBBUKQQ	CCNE2_HUMAN	Decreases Expression	[49]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Decreases Expression	[97]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Expression	[77]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[50]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Expression	[77]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Expression	[98]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Increases Expression	[89]
Collagen alpha-1(IV) chain (COL4A1)	OTL6D1YE	CO4A1_HUMAN	Increases Expression	[89]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Increases Expression	[99]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Increases Phosphorylation	[100]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[101]
Thy-1 membrane glycoprotein (THY1)	OTVONVTB	THY1_HUMAN	Increases Expression	[89]
Apolipoprotein D (APOD)	OTT77XW8	APOD_HUMAN	Increases Expression	[89]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA)	OTWJTCRK	PCCA_HUMAN	Decreases Expression	[50]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Phosphorylation	[95]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[102]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[103]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Phosphorylation	[104]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Expression	[105]
Keratin, type I cytoskeletal 18 (KRT18)	OTVLQFIP	K1C18_HUMAN	Increases Expression	[106]
Gelsolin (GSN)	OT4KS2UU	GELS_HUMAN	Decreases Expression	[49]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Increases Phosphorylation	[107]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Expression	[77]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Decreases Expression	[90]
Prosaposin (PSAP)	OTUOEKY7	SAP_HUMAN	Decreases Expression	[49]
Collagen alpha-2(IV) chain (COL4A2)	OTJK1LKN	CO4A2_HUMAN	Increases Expression	[89]
SPARC (SPARC)	OTPN90H0	SPRC_HUMAN	Increases Expression	[89]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[108]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[102]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Localization	[109]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Decreases Expression	[110]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[111]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[111]
Collagen alpha-1(VI) chain (COL6A1)	OTYKSCOB	CO6A1_HUMAN	Increases Expression	[89]
Collagen alpha-2(VI) chain (COL6A2)	OTQC6PPO	CO6A2_HUMAN	Increases Expression	[89]
ADP/ATP translocase 1 (SLC25A4)	OTKYLK2J	ADT1_HUMAN	Decreases Expression	[49]
Bone morphogenetic protein 4 (BMP4)	OTPZMDFH	BMP4_HUMAN	Decreases Expression	[53]
Elongation factor 2 (EEF2)	OTZ7SZ39	EF2_HUMAN	Decreases Expression	[49]
Glial fibrillary acidic protein (GFAP)	OTQ01ZAS	GFAP_HUMAN	Increases Expression	[112]
Interleukin-1 receptor type 1 (IL1R1)	OTTU8959	IL1R1_HUMAN	Decreases Expression	[50]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Increases Expression	[113]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[114]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Decreases Expression	[89]
Integrin beta-6 (ITGB6)	OTI3DJ7U	ITB6_HUMAN	Decreases Expression	[89]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[95]
DNA ligase 1 (LIG1)	OTEEQS43	DNLI1_HUMAN	Decreases Expression	[49]
Sodium/hydrogen exchanger 1 (SLC9A1)	OT6HNHFV	SL9A1_HUMAN	Decreases Activity	[115]
Integrin alpha-L (ITGAL)	OTCUQAIS	ITAL_HUMAN	Decreases Expression	[103]
Ephrin-A1 (EFNA1)	OTU2NUA2	EFNA1_HUMAN	Decreases Expression	[89]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3)	OTVLI4DD	TNAP3_HUMAN	Increases Expression	[77]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Expression	[102]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)	OTBZKX4P	ROA2_HUMAN	Decreases Expression	[49]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[89]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[90]
Follicle-stimulating hormone receptor (FSHR)	OT9MVMLI	FSHR_HUMAN	Decreases Expression	[53]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[111]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Increases Activity	[116]
Signal transducer CD24 (CD24)	OT7CODJ4	CD24_HUMAN	Decreases Expression	[89]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Decreases Expression	[117]
Protein S100-P (S100P)	OTJCXNJG	S100P_HUMAN	Decreases Expression	[89]
Protein S100-A4 (S100A4)	OTLRGFSQ	S10A4_HUMAN	Increases Expression	[89]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[53]
Long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADL)	OTP7Y0UF	ACADL_HUMAN	Decreases Expression	[50]
Caspase-1 (CASP1)	OTZ3YQFU	CASP1_HUMAN	Increases Expression	[98]
M-phase inducer phosphatase 3 (CDC25C)	OTPQI71S	MPIP3_HUMAN	Decreases Expression	[77]
Adenylosuccinate synthetase isozyme 2 (ADSS2)	OTW26XXB	PURA2_HUMAN	Decreases Expression	[50]
RAC-beta serine/threonine-protein kinase (AKT2)	OTBB632K	AKT2_HUMAN	Increases Phosphorylation	[118]
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1)	OTFRWOLM	HNRH1_HUMAN	Decreases Expression	[49]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Increases Expression	[50]
Syndecan-2 (SDC2)	OTEEHY1D	SDC2_HUMAN	Increases Expression	[89]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Decreases Phosphorylation	[53]
Tyrosine-protein phosphatase non-receptor type 7 (PTPN7)	OTXYSIIV	PTN7_HUMAN	Increases Expression	[50]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[50]
Fibrillin-1 (FBN1)	OTYCJT63	FBN1_HUMAN	Increases Expression	[89]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[95]
Pigment epithelium-derived factor (SERPINF1)	OTWZH98J	PEDF_HUMAN	Increases Expression	[89]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Decreases Expression	[119]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[120]
Collagen alpha-1(XVIII) chain (COL18A1)	OTJFUH6O	COIA1_HUMAN	Increases Expression	[89]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Activity	[121]
Replication factor C subunit 5 (RFC5)	OTAD79RT	RFC5_HUMAN	Decreases Expression	[50]
Serine/threonine-protein kinase mTOR (MTOR)	OTHH8KU7	MTOR_HUMAN	Decreases Phosphorylation	[111]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[122]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases Activity	[123]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Increases Expression	[124]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[125]
Isocitrate dehydrogenase , mitochondrial (IDH2)	OTTQA4PB	IDHP_HUMAN	Decreases Expression	[49]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1)	OTNWHUJ1	AL9A1_HUMAN	Increases Expression	[50]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Decreases Expression	[90]
Centromere protein F (CENPF)	OT7AG0SW	CENPF_HUMAN	Increases Expression	[38]
Caspase-4 (CASP4)	OTVQTV1L	CASP4_HUMAN	Increases Expression	[77]
NADH dehydrogenase flavoprotein 1, mitochondrial (NDUFV1)	OTEVK4WW	NDUV1_HUMAN	Decreases Expression	[49]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[126]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Decreases Expression	[90]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Expression	[50]
Cyclin-dependent kinase 7 (CDK7)	OTAO19PQ	CDK7_HUMAN	Increases Activity	[127]
Palmitoyl-protein thioesterase 1 (PPT1)	OTM3S4DE	PPT1_HUMAN	Decreases Expression	[90]
Dual specificity protein phosphatase 3 (DUSP3)	OTPJX9B4	DUS3_HUMAN	Decreases Expression	[49]
Matrix metalloproteinase-16 (MMP16)	OTSFQ2BJ	MMP16_HUMAN	Decreases Expression	[77]
Caspase-5 (CASP5)	OT0F2THD	CASP5_HUMAN	Increases Expression	[77]
Cyclin-H (CCNH)	OTKDU3SR	CCNH_HUMAN	Increases Expression	[50]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1)	OTK71JYU	TCP4_HUMAN	Decreases Expression	[50]
Epithelial membrane protein 3 (EMP3)	OTODMJ1D	EMP3_HUMAN	Increases Expression	[89]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Expression	[77]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Expression	[77]
Cadherin-11 (CDH11)	OTIZKPTF	CAD11_HUMAN	Increases Expression	[89]
Tumor protein D52 (TPD52)	OTPKSK43	TPD52_HUMAN	Decreases Expression	[89]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Cleavage	[112]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Activity	[128]
Eukaryotic initiation factor 4A-I (EIF4A1)	OTMTBX6N	IF4A1_HUMAN	Decreases Expression	[50]
Actin, aortic smooth muscle (ACTA2)	OTEDLG8E	ACTA_HUMAN	Increases Expression	[129]
Ras-related C3 botulinum toxin substrate 1 (RAC1)	OTKRO61U	RAC1_HUMAN	Decreases Expression	[49]
SH3 domain-binding protein 2 (SH3BP2)	OT90JNBS	3BP2_HUMAN	Decreases Expression	[50]
General transcription factor II-I (GTF2I)	OTUYL1TQ	GTF2I_HUMAN	Decreases Expression	[49]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Increases Expression	[50]
Cyclin-dependent kinase 6 (CDK6)	OTR95N0X	CDK6_HUMAN	Decreases Expression	[111]
Antigen peptide transporter 1 (TAP1)	OTJL27PW	TAP1_HUMAN	Increases Expression	[72]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[91]
Copper-transporting ATPase 1 (ATP7A)	OTMR3GXP	ATP7A_HUMAN	Increases Expression	[72]
Protein kinase C delta type (PRKCD)	OTSEH90E	KPCD_HUMAN	Affects Localization	[101]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[52]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[77]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[80]
Heat shock protein beta-3 (HSPB3)	OTE67YM5	HSPB3_HUMAN	Increases Expression	[50]
Lymphocyte cytosolic protein 2 (LCP2)	OT57KE22	LCP2_HUMAN	Increases Expression	[50]
FAS-associated death domain protein (FADD)	OTV7GFHH	FADD_HUMAN	Increases Expression	[77]
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1)	OTS3FVTY	M3K1_HUMAN	Increases Cleavage	[123]
MAGUK p55 subfamily member 3 (MPP3)	OTNOL0HA	MPP3_HUMAN	Increases Expression	[50]
Rho-associated protein kinase 1 (ROCK1)	OTSXYVW1	ROCK1_HUMAN	Increases Expression	[49]
Short transient receptor potential channel 3 (TRPC3)	OTNR61OD	TRPC3_HUMAN	Increases Expression	[50]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2)	OTTUU92F	ENPP2_HUMAN	Increases Expression	[89]
Protein-tyrosine kinase 6 (PTK6)	OT7NWIQ0	PTK6_HUMAN	Increases Expression	[49]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Increases Expression	[98]
Protein BTG3 (BTG3)	OT9ANHVT	BTG3_HUMAN	Increases Expression	[50]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Decreases Expression	[50]
Caprin-1 (CAPRIN1)	OTEJAMS3	CAPR1_HUMAN	Decreases Expression	[77]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Expression	[77]
Periostin (POSTN)	OTWP62UA	POSTN_HUMAN	Increases Expression	[89]
Procollagen C-endopeptidase enhancer 1 (PCOLCE)	OTJXOAN4	PCOC1_HUMAN	Increases Expression	[89]
Transcription factor E2F5 (E2F5)	OT1XWING	E2F5_HUMAN	Increases Expression	[49]
Microtubule-associated protein RP/EB family member 1 (MAPRE1)	OTCVQD60	MARE1_HUMAN	Decreases Localization	[130]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[52]
Transcriptional regulator QRICH1 (QRICH1)	OTPVAX04	QRIC1_HUMAN	Increases Phosphorylation	[131]
Parafibromin (CDC73)	OT6JASZ1	CDC73_HUMAN	Decreases Expression	[77]
Inactive caspase-12 (CASP12)	OTY2W6FG	CASPC_HUMAN	Decreases Expression	[91]
Heme A synthase COX15 (COX15)	OTUIYHIW	COX15_HUMAN	Decreases Expression	[49]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)	OTE8GBUR	RIR2B_HUMAN	Increases Expression	[132]
Cell division cycle and apoptosis regulator protein 1 (CCAR1)	OTUXLQZZ	CCAR1_HUMAN	Increases Expression	[77]
NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	OT5Q6SVK	SIR2_HUMAN	Decreases Expression	[95]
Abnormal spindle-like microcephaly-associated protein (ASPM)	OTKXQMNA	ASPM_HUMAN	Increases Expression	[92]
Phospholipid-transporting ATPase ABCA7 (ABCA7)	OT51S50X	ABCA7_HUMAN	Increases Expression	[72]
Centromere protein S (CENPS)	OTZ4J391	CENPS_HUMAN	Increases Expression	[77]
NAD-dependent protein deacylase sirtuin-6 (SIRT6)	OTF755ZO	SIR6_HUMAN	Decreases Expression	[95]
Cholesterol transporter ABCA5 (ABCA5)	OT4B9D92	ABCA5_HUMAN	Increases Expression	[72]
MAP kinase-activating death domain protein (MADD)	OTUFYVGG	MADD_HUMAN	Decreases Expression	[49]
Mucin-16 (MUC16)	OTHPPE67	MUC16_HUMAN	Decreases Expression	[133]
Rap guanine nucleotide exchange factor 5 (RAPGEF5)	OT53VS75	RPGF5_HUMAN	Increases Expression	[50]
Estrogen receptor beta (ESR2)	OTXNR2WQ	ESR2_HUMAN	Decreases Expression	[53]
Transcription factor AP-2 gamma (TFAP2C)	OTUDIW05	AP2C_HUMAN	Decreases Expression	[89]
Caspase-10 (CASP10)	OTE6J88E	CASPA_HUMAN	Increases Expression	[77]
Engulfment and cell motility protein 3 (ELMO3)	OTQHO9VM	ELMO3_HUMAN	Increases Expression	[50]
p53 apoptosis effector related to PMP-22 (PERP)	OTP0YL53	PERP_HUMAN	Increases Expression	[77]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[134]
Cell division cycle 5-like protein (CDC5L)	OTTPFUU5	CDC5L_HUMAN	Decreases Expression	[77]
M-phase phosphoprotein 6 (MPHOSPH6)	OT6E2S48	MPH6_HUMAN	Decreases Expression	[50]
Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB)	OTUKPFOK	ROAA_HUMAN	Decreases Expression	[49]
Transmembrane protein 243 (TMEM243)	OT8NQ79G	TM243_HUMAN	Increases Expression	[135]
Cell division cycle-associated protein 7 (CDCA7)	OT12HDZY	CDCA7_HUMAN	Decreases Expression	[77]
Transmembrane gamma-carboxyglutamic acid protein 4 (PRRG4)	OT2SZQI7	TMG4_HUMAN	Decreases Expression	[89]
TRIO and F-actin-binding protein (TRIOBP)	OTGB5WHC	TARA_HUMAN	Increases Expression	[50]
ATP-binding cassette sub-family B member 6 (ABCB6)	OTPGZFES	ABCB6_HUMAN	Decreases Expression	[72]
Bridging integrator 3 (BIN3)	OTMIWWDW	BIN3_HUMAN	Decreases Expression	[50]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Increases Expression	[91]
NAD-dependent protein deacetylase sirtuin-7 (SIRT7)	OT5M4OT4	SIR7_HUMAN	Decreases Expression	[95]
Olfactomedin-like protein 3 (OLFML3)	OTDN45FN	OLFL3_HUMAN	Increases Expression	[89]
G2 and S phase-expressed protein 1 (GTSE1)	OTPP742Z	GTSE1_HUMAN	Increases Expression	[50]
ETS homologous factor (EHF)	OTY6TPWD	EHF_HUMAN	Decreases Expression	[89]
Programmed cell death 1 ligand 1 (CD274)	OTJ0VFDL	PD1L1_HUMAN	Increases Expression	[136]
DNA polymerase kappa (POLK)	OTKZ38JH	POLK_HUMAN	Decreases Expression	[49]
Protein Hook homolog 1 (HOOK1)	OTTTKV7V	HOOK1_HUMAN	Decreases Expression	[89]
PR domain zinc finger protein 4 (PRDM4)	OTD9PAZJ	PRDM4_HUMAN	Decreases Expression	[50]
F-box only protein 5 (FBXO5)	OTTR957W	FBX5_HUMAN	Affects Expression	[96]
Neurabin-1 (PPP1R9A)	OTJL2TOC	NEB1_HUMAN	Decreases Expression	[49]
Matrix metalloproteinase-17 (MMP17)	OT5TMIQ6	MMP17_HUMAN	Decreases Expression	[77]
Microtubule-associated protein RP/EB family member 3 (MAPRE3)	OTSCLETV	MARE3_HUMAN	Affects Localization	[130]
Cyclin-D-binding Myb-like transcription factor 1 (DMTF1)	OTDKO9OO	DMTF1_HUMAN	Decreases Expression	[49]
RuvB-like 2 (RUVBL2)	OTGWJ4T4	RUVB2_HUMAN	Decreases Expression	[50]
C-type lectin domain family 11 member A (CLEC11A)	OT9KBH7C	CLC11_HUMAN	Increases Expression	[89]
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B)	OTND26XR	TN13B_HUMAN	Increases Expression	[77]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5)	OT03QCLM	ATF5_HUMAN	Decreases Expression	[49]
Protein-arginine deiminase type-2 (PADI2)	OTT40K94	PADI2_HUMAN	Decreases Expression	[50]
Mitochondrial import inner membrane translocase subunit Tim22 (TIMM22)	OTJMHX1V	TIM22_HUMAN	Increases Expression	[50]
Small ribosomal subunit protein mS40 (MRPS18B)	OT1K9PFX	RT18B_HUMAN	Decreases Expression	[50]
Transforming acidic coiled-coil-containing protein 3 (TACC3)	OTRNEZTA	TACC3_HUMAN	Decreases Expression	[50]
Sorting nexin-10 (SNX10)	OT05B7BT	SNX10_HUMAN	Affects Response To Substance	[55]
Superoxide dismutase (SOD2)	OT08HOR5	Q4ZJI1_HUMAN	Increases ADR	[47]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)	OT0DZGY4	E2AK3_HUMAN	Affects Response To Substance	[55]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Decreases Response To Substance	[137]
Phospholipid phosphatase 1 (PLPP1)	OT0IIMI5	PLPP1_HUMAN	Decreases Response To Substance	[138]
Interleukin-17 receptor B (IL17RB)	OT0KDNSF	I17RB_HUMAN	Decreases Response To Substance	[138]
Oxysterol-binding protein-related protein 10 (OSBPL10)	OT0TFMBE	OSB10_HUMAN	Affects Response To Substance	[55]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13)	OT0UOKIT	NDUAD_HUMAN	Affects Response To Substance	[55]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[55]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Response To Substance	[139]
Condensin complex subunit 3 (NCAPG)	OT1AI9EO	CND3_HUMAN	Affects Response To Substance	[55]
Integrin beta-5 (ITGB5)	OT21MF51	ITB5_HUMAN	Decreases Response To Substance	[75]
NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7)	OT2CHQQ1	NDUB7_HUMAN	Affects Response To Substance	[55]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Affects Response To Substance	[55]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25)	OT2MR6O2	SNR25_HUMAN	Affects Response To Substance	[55]
Epidermal growth factor-like protein 6 (EGFL6)	OT331X59	EGFL6_HUMAN	Decreases Response To Substance	[58]
Biglycan (BGN)	OT3AV6IF	PGS1_HUMAN	Affects Response To Substance	[55]
Cytidine deaminase (CDA)	OT3HXP6N	CDD_HUMAN	Affects Response To Substance	[140]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Increases Response To Substance	[138]
Solute carrier family 12 member 2 (SLC12A2)	OT3ZJ3LH	S12A2_HUMAN	Decreases Response To Substance	[138]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2)	OT4717TF	NDUB2_HUMAN	Affects Response To Substance	[55]
High mobility group protein B1 (HMGB1)	OT4B7CPF	HMGB1_HUMAN	Affects Response To Substance	[55]
Deoxycytidylate deaminase (DCTD)	OT4FLFT4	DCTD_HUMAN	Affects Response To Substance	[55]
Sorcin (SRI)	OT4R3EAC	SORCN_HUMAN	Decreases Response To Substance	[141]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Affects Response To Substance	[98]
Ubiquitin-like protein ISG15 (ISG15)	OT53QQ7N	ISG15_HUMAN	Affects Response To Substance	[55]
MARVEL domain-containing protein 1 (MARVELD1)	OT5CPOJE	MALD1_HUMAN	Increases Response To Substance	[142]
Small ribosomal subunit protein uS15m (MRPS15)	OT5HRAPP	RT15_HUMAN	Affects Response To Substance	[55]
RAC-gamma serine/threonine-protein kinase (AKT3)	OT5M2LFI	AKT3_HUMAN	Affects Response To Substance	[118]
Signal recognition particle receptor subunit alpha (SRPRA)	OT5NMYTY	SRPRA_HUMAN	Affects Response To Substance	[55]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Increases Response To Substance	[138]
Beta-sarcoglycan (SGCB)	OT5R5LAT	SGCB_HUMAN	Affects Response To Substance	[55]
Collagen alpha-2(V) chain (COL5A2)	OT5VOSQE	CO5A2_HUMAN	Decreases Response To Substance	[58]
Transmembrane protein 135 (TMEM135)	OT63ZT3X	TM135_HUMAN	Affects Response To Substance	[55]
Farnesyl pyrophosphate synthase (FDPS)	OT6CKWV5	FPPS_HUMAN	Increases Response To Substance	[75]
Ferritin heavy chain (FTH1)	OT6IFS0O	FRIH_HUMAN	Decreases Response To Substance	[75]
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Increases Response To Substance	[75]
Claudin-3 (CLDN3)	OT71MN9S	CLD3_HUMAN	Decreases Response To Substance	[138]
Plasminogen activator inhibitor 2 (SERPINB2)	OT72QLZB	PAI2_HUMAN	Affects Response To Substance	[55]
DNA-binding protein RFX5 (RFX5)	OT73KJ5P	RFX5_HUMAN	Decreases Response To Substance	[75]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Response To Substance	[143]
Large ribosomal subunit protein P1 (RPLP1)	OT7B0SIB	RLA1_HUMAN	Decreases Response To Substance	[75]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Decreases Response To Substance	[144]
Nucleolar and spindle-associated protein 1 (NUSAP1)	OT85HIJ5	NUSAP_HUMAN	Affects Response To Substance	[55]
Peroxisomal multifunctional enzyme type 2 (HSD17B4)	OT8733D7	DHB4_HUMAN	Affects Response To Substance	[55]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Response To Substance	[145]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)	OT8KME51	BUB1B_HUMAN	Affects Response To Substance	[146]
Thrombomodulin (THBD)	OT8VHLKY	TRBM_HUMAN	Decreases Response To Substance	[147]
Transcriptional repressor CTCF (CTCF)	OT8ZB70U	CTCF_HUMAN	Decreases Response To Substance	[75]
Neuron navigator 3 (NAV3)	OT97M1TR	NAV3_HUMAN	Affects Response To Substance	[55]
Solute carrier family 22 member 18 (SLC22A18)	OT9C3KR4	S22AI_HUMAN	Decreases Response To Substance	[138]
Gamma-interferon-inducible lysosomal thiol reductase (IFI30)	OT9DERT1	GILT_HUMAN	Decreases Response To Substance	[75]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Response To Substance	[75]
Beta-glucuronidase (GUSB)	OT9N1DK3	BGLR_HUMAN	Affects Response To Substance	[55]
FXYD domain-containing ion transport regulator 3 (FXYD3)	OT9PPRHE	FXYD3_HUMAN	Increases Response To Substance	[75]
Proteasome subunit beta type-6 (PSMB6)	OT9VXPNW	PSB6_HUMAN	Affects Response To Substance	[55]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3)	OTA2TBWS	HMGN3_HUMAN	Affects Response To Substance	[55]
Atypical chemokine receptor 3 (ACKR3)	OTA6GA4F	ACKR3_HUMAN	Decreases Response To Substance	[75]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4)	OTA6ICI2	NUD4B_HUMAN	Affects Response To Substance	[55]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Response To Substance	[148]
Proteasome subunit alpha type-4 (PSMA4)	OTAD2XXI	PSA4_HUMAN	Affects Response To Substance	[55]
POM121 and ZP3 fusion protein (POMZP3)	OTAH2JOK	POZP3_HUMAN	Affects Response To Substance	[55]
Mediator of RNA polymerase II transcription subunit 4 (MED4)	OTALFN4S	MED4_HUMAN	Affects Response To Substance	[55]
snRNA-activating protein complex subunit 1 (SNAPC1)	OTAPN1NI	SNPC1_HUMAN	Increases Response To Substance	[138]
Collagen alpha-3(VI) chain (COL6A3)	OTAS6R6I	CO6A3_HUMAN	Affects Response To Substance	[55]
MAP kinase-activated protein kinase 5 (MAPKAPK5)	OTAZHPVK	MAPK5_HUMAN	Affects Response To Substance	[55]
Desmoplakin (DSP)	OTB2MOP8	DESP_HUMAN	Affects Response To Substance	[55]
Large ribosomal subunit protein mL40 (MRPL40)	OTB2QZDY	RM40_HUMAN	Affects Response To Substance	[55]
Large ribosomal subunit protein uL16 (RPL10)	OTBHOZGC	RL10_HUMAN	Affects Response To Substance	[55]
Prominin-1 (PROM1)	OTBHV8NX	PROM1_HUMAN	Decreases Response To Substance	[149]
Probable ATP-dependent RNA helicase DDX23 (DDX23)	OTBJHS8C	DDX23_HUMAN	Affects Response To Substance	[55]
Coatomer subunit epsilon (COPE)	OTBKHBT7	COPE_HUMAN	Affects Response To Substance	[55]
Protein FAM3C (FAM3C)	OTBR6U9G	FAM3C_HUMAN	Affects Response To Substance	[55]
Transmembrane protein 134 (TMEM134)	OTBX9H9D	TM134_HUMAN	Affects Response To Substance	[55]
Tight junction protein ZO-3 (TJP3)	OTC1K8HC	ZO3_HUMAN	Decreases Response To Substance	[138]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Affects Response To Substance	[150]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C)	OTCLOV90	CDN2C_HUMAN	Affects Response To Substance	[55]
Cytochrome c oxidase copper chaperone (COX17)	OTCP4LH2	COX17_HUMAN	Affects Response To Substance	[55]
Trefoil factor 1 (TFF1)	OTCYQH4F	TFF1_HUMAN	Increases Response To Substance	[75]
S-phase kinase-associated protein 2 (SKP2)	OTD5B41X	SKP2_HUMAN	Affects Response To Substance	[55]
Integrin alpha-1 (ITGA1)	OTDITIST	ITA1_HUMAN	Increases Response To Substance	[58]
Stathmin (STMN1)	OTDJ4RV0	STMN1_HUMAN	Affects Response To Substance	[151]
Gamma-adducin (ADD3)	OTDRSHAZ	ADDG_HUMAN	Affects Response To Substance	[55]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Decreases Response To Substance	[75]
Superkiller complex protein 8 (SKIC8)	OTDSQYDN	SKI8_HUMAN	Affects Response To Substance	[55]
DNA-binding protein RFXANK (RFXANK)	OTDX1026	RFXK_HUMAN	Affects Response To Substance	[55]
Transcription initiation factor TFIID subunit 1 (TAF1)	OTDYS5G4	TAF1_HUMAN	Affects Response To Substance	[152]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7)	OTE0EG10	EFCB7_HUMAN	Affects Response To Substance	[55]
Glucose-6-phosphate isomerase (GPI)	OTEGSRXG	G6PI_HUMAN	Affects Response To Substance	[55]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)	OTEOT8GI	GFRP_HUMAN	Decreases Response To Substance	[138]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13)	OTESFZSO	PTN13_HUMAN	Increases Response To Substance	[138]
Rho GDP-dissociation inhibitor 1 (ARHGDIA)	OTEXWJDO	GDIR1_HUMAN	Affects Response To Substance	[153]
Caveolin-1 (CAV1)	OTEZUR1L	CAV1_HUMAN	Increases Response To Substance	[75]
Serglycin (SRGN)	OTFAVSX0	SRGN_HUMAN	Affects Response To Substance	[55]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A)	OTFBU4GD	P3C2A_HUMAN	Affects Response To Substance	[55]
Laminin subunit alpha-2 (LAMA2)	OTFROQWE	LAMA2_HUMAN	Increases Response To Substance	[58]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Affects Response To Substance	[55]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1)	OTGPN3P8	TIA1_HUMAN	Affects Response To Substance	[55]
Stanniocalcin-1 (STC1)	OTGVVXYF	STC1_HUMAN	Affects Response To Substance	[55]
Gasdermin-D (GSDMD)	OTH39BKI	GSDMD_HUMAN	Affects Response To Substance	[98]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Affects Response To Substance	[55]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Increases Response To Substance	[57]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Response To Substance	[154]
Metallothionein-2 (MT2A)	OTHOACHD	MT2_HUMAN	Increases Response To Substance	[75]
Neurogenic locus notch homolog protein 1 (NOTCH1)	OTI1WADQ	NOTC1_HUMAN	Decreases Response To Substance	[155]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Affects Response To Substance	[55]
G2/mitotic-specific cyclin-B2 (CCNB2)	OTIEXTDK	CCNB2_HUMAN	Affects Response To Substance	[55]
Polycystin-2 (PKD2)	OTIXBU8H	PKD2_HUMAN	Increases Response To Substance	[138]
G/T mismatch-specific thymine DNA glycosylase (TDG)	OTJB0YIH	TDG_HUMAN	Affects Response To Substance	[55]
E3 ubiquitin-protein ligase FANCL (FANCL)	OTJC7QPQ	FANCL_HUMAN	Affects Response To Substance	[55]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1)	OTJISZOX	PLCE1_HUMAN	Decreases Response To Substance	[138]
Transmembrane protein 168 (TMEM168)	OTJKZ6G9	TM168_HUMAN	Affects Response To Substance	[55]
Plakophilin-2 (PKP2)	OTJOVF68	PKP2_HUMAN	Decreases Response To Substance	[138]
C-X-C chemokine receptor type 6 (CXCR6)	OTK9R50G	CXCR6_HUMAN	Decreases Response To Substance	[75]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Increases Response To Substance	[138]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1)	OTKBUQXP	NDUA1_HUMAN	Affects Response To Substance	[55]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Increases Response To Substance	[138]
Serine/threonine-protein kinase PLK2 (PLK2)	OTKMJXJ8	PLK2_HUMAN	Increases ADR	[47]
Galectin-4 (LGALS4)	OTKQCG0H	LEG4_HUMAN	Decreases Response To Substance	[138]
Methylsterol monooxygenase 1 (MSMO1)	OTKV62RZ	MSMO1_HUMAN	Affects Response To Substance	[55]
Leukocyte surface antigen CD47 (CD47)	OTLDZ0KZ	CD47_HUMAN	Decreases Response To Substance	[75]
Pyruvate kinase PKM (PKM)	OTLHHMC2	KPYM_HUMAN	Affects Response To Substance	[55]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Increases Response To Substance	[139]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Increases Response To Substance	[57]
Peptidyl-prolyl cis-trans isomerase B (PPIB)	OTLPH6KN	PPIB_HUMAN	Affects Response To Substance	[55]
Annexin A8 (ANXA8)	OTLSSQCY	ANXA8_HUMAN	Increases Response To Substance	[138]
Keratin, type II cytoskeletal 7 (KRT7)	OTLT3JFN	K2C7_HUMAN	Increases Response To Substance	[138]
Lysosome-associated membrane glycoprotein 2 (LAMP2)	OTLUGEJC	LAMP2_HUMAN	Affects Response To Substance	[55]
Peroxiredoxin-2 (PRDX2)	OTLWCY9T	PRDX2_HUMAN	Affects Response To Substance	[55]
Hemicentin-1 (HMCN1)	OTLZAS0P	HMCN1_HUMAN	Increases Response To Substance	[58]
Furin (FURIN)	OTM2665Z	FURIN_HUMAN	Decreases Response To Substance	[75]
NADH dehydrogenase iron-sulfur protein 8, mitochondrial (NDUFS8)	OTMEAWKO	NDUS8_HUMAN	Affects Response To Substance	[55]
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8)	OTMFG2YY	ALG8_HUMAN	Affects Response To Substance	[55]
Glutathione S-transferase Mu 5 (GSTM5)	OTMMBFY8	GSTM5_HUMAN	Decreases Response To Substance	[75]
Unconventional myosin-Va (MYO5A)	OTMWLP3E	MYO5A_HUMAN	Increases Response To Substance	[138]
Integral membrane protein 2B (ITM2B)	OTMXEPXB	ITM2B_HUMAN	Affects Response To Substance	[55]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2)	OTMZD4PW	SUCB1_HUMAN	Affects Response To Substance	[55]
Four and a half LIM domains protein 1 (FHL1)	OTN535SU	FHL1_HUMAN	Increases Response To Substance	[138]
L-lactate dehydrogenase A chain (LDHA)	OTN7K4XB	LDHA_HUMAN	Increases Response To Substance	[156]
Proto-oncogene serine/threonine-protein kinase mos (MOS)	OTNMQPFJ	MOS_HUMAN	Increases ADR	[47]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Increases ADR	[47]
Calcium-activated potassium channel subunit alpha-1 (KCNMA1)	OTNYXOZO	KCMA1_HUMAN	Affects Response To Substance	[55]
G-protein coupled receptor 35 (GPR35)	OTO23NRK	GPR35_HUMAN	Decreases Response To Substance	[138]
Histone deacetylase 9 (HDAC9)	OTO8O0LF	HDAC9_HUMAN	Increases Response To Substance	[138]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Response To Substance	[157]
Arginine/serine-rich protein 1 (RSRP1)	OTOAZLCL	RSRP1_HUMAN	Affects Response To Substance	[55]
Malectin (MLEC)	OTOPGRF5	MLEC_HUMAN	Affects Response To Substance	[55]
Oncostatin-M-specific receptor subunit beta (OSMR)	OTORWHPL	OSMR_HUMAN	Increases Response To Substance	[138]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Decreases Response To Substance	[158]
Delta(24)-sterol reductase (DHCR24)	OTP301JW	DHC24_HUMAN	Affects Response To Substance	[55]
Interleukin-13 receptor subunit alpha-2 (IL13RA2)	OTPC2G0X	I13R2_HUMAN	Affects Response To Substance	[55]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[55]
Prostaglandin E synthase 3 (PTGES3)	OTPPQWI0	TEBP_HUMAN	Affects Response To Substance	[55]
Large ribosomal subunit protein uL23 (RPL23A)	OTPYLCCX	RL23A_HUMAN	Decreases Response To Substance	[75]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Increases Response To Substance	[75]
Eukaryotic translation initiation factor 5A-1 (EIF5A)	OTQ8DJX5	IF5A1_HUMAN	Increases Response To Substance	[138]
Membrane cofactor protein (CD46)	OTQ8NWJD	MCP_HUMAN	Increases Response To Substance	[75]
Glutamine--fructose-6-phosphate aminotransferase 1 (GFPT1)	OTQBDO45	GFPT1_HUMAN	Decreases Response To Substance	[138]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Decreases Response To Substance	[159]
MAPK/MAK/MRK overlapping kinase (MOK)	OTQK7M9V	MOK_HUMAN	Affects Response To Substance	[55]
Keratin, type I cytoskeletal 23 (KRT23)	OTQW6UAG	K1C23_HUMAN	Increases Response To Substance	[58]
Fibroblast growth factor 5 (FGF5)	OTQXGHBY	FGF5_HUMAN	Affects Response To Substance	[55]
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Affects Response To Substance	[55]
Nuclear body protein SP140 (SP140)	OTQZHFMT	SP140_HUMAN	Affects Response To Substance	[55]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI)	OTR443C5	BGH3_HUMAN	Decreases Response To Substance	[58]
E3 ubiquitin-protein ligase CHFR (CHFR)	OTRAD2TT	CHFR_HUMAN	Decreases Response To Substance	[160]
Large ribosomal subunit protein mL63 (MRPL57)	OTRB659E	RT63_HUMAN	Affects Response To Substance	[55]
Protein CREG1 (CREG1)	OTRHJ8HK	CREG1_HUMAN	Affects Response To Substance	[55]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A)	OTRHPFO2	AN32A_HUMAN	Affects Response To Substance	[55]
Retinol-binding protein 1 (RBP1)	OTRP1MFC	RET1_HUMAN	Increases Response To Substance	[138]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Response To Substance	[138]
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Increases Response To Substance	[138]
Arrestin-C (ARR3)	OTRZ00CH	ARRC_HUMAN	Decreases Response To Substance	[75]
MHC class I polypeptide-related sequence B (MICB)	OTS2DVDW	MICB_HUMAN	Increases Response To Substance	[138]
Latent-transforming growth factor beta-binding protein 2 (LTBP2)	OTS88GSD	LTBP2_HUMAN	Affects Response To Substance	[55]
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B)	OTS9YK3E	KCC2B_HUMAN	Affects Response To Substance	[55]
Lumican (LUM)	OTSRC874	LUM_HUMAN	Decreases Response To Substance	[58]
Rhotekin (RTKN)	OTSS8XR6	RTKN_HUMAN	Decreases Response To Substance	[161]
3-phosphoinositide-dependent protein kinase 1 (PDPK1)	OTT09ZVP	PDPK1_HUMAN	Decreases Response To Substance	[145]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Affects Response To Substance	[55]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Decreases Response To Substance	[58]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)	OTT5JX1F	LITAF_HUMAN	Affects Response To Substance	[55]
Nucleophosmin (NPM1)	OTTBYYT0	NPM_HUMAN	Decreases Response To Substance	[162]
Amyloid beta precursor like protein 2 (APLP2)	OTTFE53M	APLP2_HUMAN	Affects Response To Substance	[55]
Collagen alpha-1(XV) chain (COL15A1)	OTTFKK18	COFA1_HUMAN	Decreases Response To Substance	[58]
Fascin (FSCN1)	OTTGIHTM	FSCN1_HUMAN	Increases Response To Substance	[138]
Keratin, type I cytoskeletal 13 (KRT13)	OTTYSKGX	K1C13_HUMAN	Decreases Response To Substance	[75]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Decreases Response To Substance	[163]
C-X-C chemokine receptor type 4 (CXCR4)	OTUFSBX2	CXCR4_HUMAN	Decreases Response To Substance	[75]
N-acetylgalactosaminyltransferase 7 (GALNT7)	OTUJSCAO	GALT7_HUMAN	Affects Response To Substance	[55]
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (DAD1)	OTUUNQBT	DAD1_HUMAN	Increases ADR	[47]
Mitochondrial Rho GTPase 2 (RHOT2)	OTV8WT2L	MIRO2_HUMAN	Affects Response To Substance	[55]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Decreases Response To Substance	[58]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Response To Substance	[57]
Integrin beta-1-binding protein 1 (ITGB1BP1)	OTVQFNGS	ITBP1_HUMAN	Affects Response To Substance	[55]
U2 small nuclear ribonucleoprotein A' (SNRPA1)	OTWJZFAP	RU2A_HUMAN	Affects Response To Substance	[55]
Decorin (DCN)	OTWLJL7K	PGS2_HUMAN	Decreases Response To Substance	[58]
Glypican-3 (GPC3)	OTWS8WSW	GPC3_HUMAN	Increases Response To Substance	[58]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Response To Substance	[164]
Transmembrane protein 59 (TMEM59)	OTX4EKES	TMM59_HUMAN	Affects Response To Substance	[55]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15)	OTX8SZOT	NUD15_HUMAN	Affects Response To Substance	[55]
Metallothionein-1E (MT1E)	OTXJKU4Y	MT1E_HUMAN	Increases Response To Substance	[75]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3)	OTXL10N9	NDUA3_HUMAN	Affects Response To Substance	[55]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Affects Response To Substance	[146]
Neuroendocrine protein 7B2 (SCG5)	OTXSJMT1	7B2_HUMAN	Affects Response To Substance	[55]
Peripheral myelin protein 22 (PMP22)	OTXWYWCZ	PMP22_HUMAN	Decreases Response To Substance	[75]
Collagen alpha-2(I) chain (COL1A2)	OTY7G382	CO1A2_HUMAN	Increases Response To Substance	[58]
Bone morphogenetic protein 7 (BMP7)	OTYATP2K	BMP7_HUMAN	Increases Response To Substance	[75]
Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PPP1CB)	OTYFTYFR	PP1B_HUMAN	Affects Response To Substance	[55]
Ferritin light chain (FTL)	OTYQA8A6	FRIL_HUMAN	Decreases Response To Substance	[75]
Proteasome subunit beta type-1 (PSMB1)	OTYRFBAH	PSB1_HUMAN	Affects Response To Substance	[55]
Procathepsin L (CTSL)	OTYTUW29	CATL1_HUMAN	Increases Response To Substance	[75]
ADP-ribosylation factor 3 (ARF3)	OTYYQX85	ARF3_HUMAN	Affects Response To Substance	[55]
V-type proton ATPase catalytic subunit A (ATP6V1A)	OTYZ2S9E	VATA_HUMAN	Affects Response To Substance	[55]
Mitochondrial import inner membrane translocase subunit Tim13 (TIMM13)	OTYZQJD3	TIM13_HUMAN	Affects Response To Substance	[55]
Erythropoietin (EPO)	OTZ90CN4	EPO_HUMAN	Decreases Response To Substance	[165]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Affects Response To Substance	[55]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Affects Response To Substance	[55]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Affects Response To Substance	[55]

References

• [1] ClinicalTrials.gov (NCT00585052) A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
• [2] Lovastatin FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2739).
• [4] Clinical pipeline report, company report or official report of CardioPharma Wilmington.
• [5] Paclitaxel FDA Label
• [6] Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
• [7] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [8] A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
• [9] Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
• [10] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [11] Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
• [12] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [13] Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
• [14] Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005 Jun;46(6):1239-47. doi: 10.1194/jlr.M400511-JLR200. Epub 2005 Mar 16.
• [15] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [16] Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase-deficient cell line. Biochem J. 2009 May 13;420(2):305-15.
• [17] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [18] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [19] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [20] Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Biochem Pharmacol. 1993 Jun 9;45(11):2203-8.
• [21] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [22] Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem. 2007 Jul 6;282(27):19273-81. doi: 10.1074/jbc.M610350200. Epub 2007 May 1.
• [23] Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 2009 May;63(6):997-1005. doi: 10.1007/s00280-008-0830-7. Epub 2008 Sep 3.
• [24] Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol. 2005 Sep;130(6):912-25. doi: 10.1111/j.1365-2141.2005.05696.x.
• [25] Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
• [26] Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6. doi: 10.1210/jc.2002-021834.
• [27] Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009 May;21(5):1317-22. doi: 10.3892/or_00000357.
• [28] Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
• [29] Protection against the Neurotoxic Effects of -Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of 7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. Am J Pathol. 2018 Apr;188(4):1081-1093. doi: 10.1016/j.ajpath.2017.11.020. Epub 2018 Jan 16.
• [30] Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Exp Cell Res. 1999 Oct 10;252(1):144-53. doi: 10.1006/excr.1999.4608.
• [31] Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP. Mol Cell Biochem. 2010 Dec;345(1-2):1-11. doi: 10.1007/s11010-010-0553-z. Epub 2010 Aug 9.
• [32] Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010 Sep 11;41(1):118-24. doi: 10.1016/j.ejps.2010.05.021. Epub 2010 Jun 8.
• [33] Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999 Aug;5(8):2223-9.
• [34] Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr. 1999 Apr;129(4):804-13. doi: 10.1093/jn/129.4.804.
• [35] In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung. 2008 Jan-Feb;186(1):45-54. doi: 10.1007/s00408-007-9053-7. Epub 2007 Nov 22.
• [36] Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer. 2006 May 15;118(10):2390-8. doi: 10.1002/ijc.21799.
• [37] Indirect co-cultivation of HepG2 with differentiated THP-1 cells induces AHR signalling and release of pro-inflammatory cytokines. Toxicol In Vitro. 2020 Oct;68:104957. doi: 10.1016/j.tiv.2020.104957. Epub 2020 Jul 30.
• [38] Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.
• [39] Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett. 2007 Feb 2;412(3):211-6. doi: 10.1016/j.neulet.2006.07.045. Epub 2007 Jan 17.
• [40] Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol. 2008 Feb;86(3):273-83. doi: 10.1007/s11060-007-9475-3. Epub 2007 Oct 11.
• [41] Lovastatin-induced apoptosis in thyroid cells: involvement of cytochrome c and lamin B. Eur J Endocrinol. 2001 Nov;145(5):645-50. doi: 10.1530/eje.0.1450645.
• [42] Inhibitory effects of clinical reagents having anti-oxidative activity on transforming growth factor-1-induced expression of -smooth muscle actin in human fetal lung fibroblasts. J Toxicol Sci. 2011;36(6):733-40. doi: 10.2131/jts.36.733.
• [43] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [44] Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006 Mar;316(3):1098-106. doi: 10.1124/jpet.105.093393. Epub 2005 Nov 8.
• [45] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [46] NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
• [47] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [48] Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
• [49] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [50] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [51] Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res. 2008 May-Jun;28(3A):1593-602.
• [52] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
• [53] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [54] 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006 Jan 8;231(1):49-64. doi: 10.1016/j.canlet.2005.01.018.
• [55] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [56] Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
• [57] Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
• [58] Microarray-based detection and expression analysis of extracellular matrix proteins in drug?resistant ovarian cancer cell lines. Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.
• [59] Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med. 2011 Jan 26;3(67):67ra7. doi: 10.1126/scitranslmed.3001922.
• [60] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [61] Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
• [62] Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
• [63] Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
• [64] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [65] Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
• [66] Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
• [67] MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
• [68] Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
• [69] Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
• [70] Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
• [71] FaDu cell characteristics induced by multidrug resistance. Oncol Rep. 2011 Nov;26(5):1189-95. doi: 10.3892/or.2011.1418. Epub 2011 Aug 10.
• [72] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [73] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [74] Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004 Nov 15;64(22):8397-404. doi: 10.1158/0008-5472.CAN-04-1612.
• [75] cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
• [76] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [77] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [78] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [79] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [80] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [81] CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
• [82] A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN). Endocrinology. 2004 Apr;145(4):1860-9.
• [83] The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 2005 May;19(5):1170-80.
• [84] Paclitaxel inhibits N-acetyltransferase activity and gene expression in human stomach tumor cells (SC-M1). Res Commun Mol Pathol Pharmacol. 2004;115-116:21-38.
• [85] Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol. 2009 Jun 16;53(24):2298-305.
• [86] Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32.
• [87] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [88] Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
• [89] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [90] Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells. Chem Res Toxicol. 2019 Feb 18;32(2):255-264. doi: 10.1021/acs.chemrestox.8b00269. Epub 2019 Jan 22.
• [91] Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
• [92] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [93] Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005 Jul;4(7):716-9. doi: 10.4161/cbt.4.7.1782. Epub 2005 Jul 2.
• [94] Regulation of retinoschisin secretion in Weri-Rb1 cells by the F-actin and microtubule cytoskeleton. PLoS One. 2011;6(6):e20707. doi: 10.1371/journal.pone.0020707. Epub 2011 Jun 27.
• [95] Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression. Environ Toxicol. 2021 Nov;36(11):2206-2216. doi: 10.1002/tox.23334. Epub 2021 Jul 16.
• [96] CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
• [97] Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Chem Biol Interact. 2020 Jan 5;315:108865. doi: 10.1016/j.cbi.2019.108865. Epub 2019 Oct 16.
• [98] The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
• [99] The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol. 2009 May;25(5):287-93. doi: 10.1080/09513590802530924.
• [100] Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int. 2003 Apr;42(5):419-29. doi: 10.1016/s0197-0186(02)00132-8.
• [101] Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
• [102] Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 7;25(3):94-102. doi: 10.1016/j.cyto.2003.10.004.
• [103] Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
• [104] pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
• [105] Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
• [106] Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol. 2014 May;29(7):804-13. doi: 10.1002/tox.21809. Epub 2012 Aug 21.
• [107] ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol. 2004 Jun;24(6):1499-504.
• [108] Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem. 1999 Mar 19;274(12):8208-16. doi: 10.1074/jbc.274.12.8208.
• [109] Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
• [110] Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
• [111] Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. J Biochem Mol Toxicol. 2023 May;37(5):e23313. doi: 10.1002/jbt.23313. Epub 2023 Jan 22.
• [112] Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
• [113] Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
• [114] Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
• [115] Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res. 2003 Jun;9(6):2366-73.
• [116] Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999 Jul;5(7):1876-83.
• [117] Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway. Breast Cancer Res Treat. 2011 Jul;128(1):57-68. doi: 10.1007/s10549-010-1076-8. Epub 2010 Jul 28.
• [118] Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008 Feb;13(2):259-71. doi: 10.1007/s10495-007-0165-6.
• [119] Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
• [120] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [121] Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci. 2010 May;115(1):118-30. doi: 10.1093/toxsci/kfq028. Epub 2010 Jan 27.
• [122] Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res. 2005 Sep;23(5):988-94. doi: 10.1016/j.orthres.2005.01.018. Epub 2005 Apr 25.
• [123] Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol. 2001 Feb;59(2):254-62. doi: 10.1124/mol.59.2.254.
• [124] Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):55-62. doi: 10.1016/j.taap.2005.06.020. Epub 2005 Jul 26.
• [125] Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol. 2005 Jul 1;70(1):13-21. doi: 10.1016/j.bcp.2005.04.017.
• [126] PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol. 2009 Apr 15;77(8):1348-57. doi: 10.1016/j.bcp.2009.01.008. Epub 2009 Jan 24.
• [127] Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 1997;2(5):463-70. doi: 10.1023/a:1026422111457.
• [128] Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs. 2001 Nov;12(10):797-800. doi: 10.1097/00001813-200111000-00002.
• [129] Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
• [130] Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.
• [131] Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
• [132] Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
• [133] 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. Int J Clin Oncol. 2001 Jun;6(3):128-31. doi: 10.1007/pl00012094.
• [134] Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther. 2006 Apr;5(4):380-5. doi: 10.4161/cbt.5.4.2477. Epub 2006 Apr 4.
• [135] MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene. 2004 Sep 29;340(1):53-9. doi: 10.1016/j.gene.2004.06.013.
• [136] Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
• [137] High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010 Jul 1;70(13):5486-96. doi: 10.1158/0008-5472.CAN-10-0713. Epub 2010 Jun 8.
• [138] Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
• [139] E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
• [140] Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
• [141] [Correlation of sorcin overexpression to multidrug resistance of human gastric cancer cell line SGC7901]. Ai Zheng. 2008 Apr;27(4):337-42.
• [142] Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
• [143] CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
• [144] Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. doi: 10.1007/s11095-006-0136-6. Epub 2006 Jun 8.
• [145] Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
• [146] Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
• [147] Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology. 2016 Jul 15;365:48-58. doi: 10.1016/j.tox.2016.07.016. Epub 2016 Jul 27.
• [148] CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010 Dec;30(12):4791-8.
• [149] CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mllerian tumor). Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.
• [150] ATF3 inhibits arsenic-induced malignant transformation of human bronchial epithelial cells by attenuating inflammation. Toxicology. 2021 Aug;460:152890. doi: 10.1016/j.tox.2021.152890. Epub 2021 Aug 6.
• [151] Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006 Dec;5(12):3248-57. doi: 10.1158/1535-7163.MCT-06-0227.
• [152] MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. doi: 10.1002/jbt.23380. Epub 2023 May 3.
• [153] Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells. Anticancer Drugs. 2007 Mar;18(3):333-40. doi: 10.1097/CAD.0b013e328011fd7f.
• [154] Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol. 2011 Nov 15;82(10):1384-90. doi: 10.1016/j.bcp.2011.06.007. Epub 2011 Jun 13.
• [155] Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. Environ Toxicol. 2021 Sep;36(9):1758-1764. doi: 10.1002/tox.23296. Epub 2021 May 28.
• [156] Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011 Mar 24;54(6):1599-612. doi: 10.1021/jm101007q. Epub 2011 Feb 18.
• [157] Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells. Chem Biol Interact. 2015 Jun 25;235:17-26. doi: 10.1016/j.cbi.2015.04.005. Epub 2015 Apr 10.
• [158] Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41. doi: 10.1073/pnas.1934692100. Epub 2003 Sep 16.
• [159] Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005 Jun;124(6):1300-7. doi: 10.1111/j.0022-202X.2005.23720.x.
• [160] Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
• [161] Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004 Nov 18;23(54):8731-42. doi: 10.1038/sj.onc.1208106.
• [162] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [163] Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2011 Jun 1;9(6):681-9. doi: 10.6004/jnccn.2011.0056.
• [164] Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
• [165] Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis. 2006 Dec;24(3):525-30. doi: 10.1016/j.nbd.2006.08.014. Epub 2006 Sep 28.